OR WAIT null SECS
The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.
New data presented at the American Society of Hematology (ASH) 2020 Annual Meeting this week showed the long-term benefit of voxelotor (Oxbryta) for the treatment of vaso-occlusive incidences over 72 weeks in patients with sickle cell disease.
The phase 3 HOPE Study builds upon a set foundation for the Global Blood Therapeutics (GBT) once-daily oral therapy originally approved for the treatment of sickle cell disease in 2019, establishing a long-term portfolio in real-world patients for a litany of disease factors.
Patients administered 1500 mg voxelotor reported sustained improvements to their hemoglobin levels and hemolysis metrics over the observed period, supporting the use of the agent for overall sickle anemia and hemolysis reduction. The findings even indicate the potential for reduced morbidity and mortality of sickle cell disease via the deoxygenated sickle hemoglobin polymerization inhibitor.
During an ASH 2020 episode of DocTalk, HCPLive® spoke with HOPE Study presenter Elliott Vichinski, MD, Chief of Hematology/Oncology at the University of California-San Francisco Benioff Children’s Hospital.
Vichinsky discussed the newest HOPE findings, the clinical history of sickle cell disease, and what may come next for the burgeoning portfolio of voxelotor.
Subscribe or listen to DocTalk on your favorite platforms: